Steven Feldman to Interleukin-17
This is a "connection" page, showing publications Steven Feldman has written about Interleukin-17.
Connection Strength
1.881
-
Veverka KK, Feldman SR. Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism? J Dermatolog Treat. 2018 Aug; 29(5):475-480.
Score: 0.597
-
Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018 Feb; 29(1):13-18.
Score: 0.577
-
Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012 Oct 15; 18(10):1.
Score: 0.419
-
Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
Score: 0.170
-
Sandoval LF, Pierce A, Feldman SR. Systemic therapies for psoriasis: an evidence-based update. Am J Clin Dermatol. 2014 Jul; 15(3):165-80.
Score: 0.118